Siemens Healthineers Rebrands PETNET Solutions and AdAcAp Molecular Imaging, Launching a Unified Global Radiopharma Identity
Siemens Healthineers has officially announced a sweeping brand transformation across its radiopharmaceutical operations, uniting PETNET Solutions Inc. and Advanced Accelerator Applications (AdAcAp) Molecular Imaging under the single global identity of Siemens Healthineers. Effective immediately, both organizations—long-standing leaders in the production and distribution of PET imaging agents—will operate as part of the company’s expanding Radiopharma business segment. The full transition, including visual identity changes, system integrations, and market-facing updates, is expected to be completed within the next 12 months.
This newly consolidated identity marks a significant milestone for Siemens Healthineers, already recognized as the world’s largest manufacturer and distributor of PET radiopharmaceuticals. By bringing PETNET Solutions and AdAcAp Molecular Imaging together under one unified banner, the company aims to accelerate innovation, enhance operational efficiency, and deliver a more seamless experience for imaging centers, clinicians, and patients around the world.
Strengthening the World’s Largest PET Radiopharmaceutical Network
Siemens Healthineers operates an unparalleled global network dedicated to radiopharmaceutical production. With 60 specialized facilities across nine countries, the company manufactures more than 100,000 batches of sterile PET radiopharmaceuticals every year. These agents are essential components of PET imaging, supporting diagnosis in oncology, cardiology, neurology, and, increasingly, precision-targeted cancer therapies.
As the demand for theranostic services grows rapidly, Siemens Healthineers’ robust production footprint has positioned it at the forefront of delivering radiopharmaceuticals that support this evolving care model. Theranostics—an innovative approach that links diagnostic imaging with targeted therapy—relies heavily on consistent, high-quality PET agents to identify eligible patients and monitor treatment response. Through the combined capabilities of PETNET and AdAcAp Molecular Imaging, Siemens Healthineers is now able to meet growing global demand with greater scale and efficiency.
Rebranding Follows Major European Expansion
The timing of the brand unification is closely tied to Siemens Healthineers’ acquisition strategy. In December 2024, the company expanded its European footprint through the acquisition of AdAcAp Molecular Imaging from Novartis, a move that added significant radiopharmaceutical manufacturing capacity across Europe. The newly acquired network included 13 PET radiopharmaceutical production sites distributed throughout France, Spain, Portugal, Italy, and Germany.
These facilities now complement PETNET Solutions’ substantial network of 47 cyclotron-powered radiopharmacies, primarily located in the United States. Together, the combined infrastructure strengthens Siemens Healthineers’ ability to deliver on-demand PET radiopharmaceuticals, which often require same-day production and delivery due to the short half-lives of isotopes used in PET imaging.
By integrating all facilities and operations under one brand, Siemens Healthineers aims to reflect its expanded capabilities and present a unified value proposition to healthcare systems worldwide.
Leadership Perspective: A Strategic Move to Accelerate Innovation
Barry Scott, head of the Radiopharma business at Siemens Healthineers, emphasized the strategic importance of the rebrand. According to Scott, the decision reflects both the company’s long-term vision and the current momentum within the radiopharmaceutical industry.
“Siemens Healthineers companies PETNET Solutions and Advanced Accelerator Applications have served as cornerstones of our radiopharma business,” Scott said. “Given current market dynamics and the momentum in the radiopharmaceutical industry, the time is right to unify under the brand Siemens Healthineers. This strategic move unites our people, products, and purpose to deliver even greater value to customers and patients as well as accelerate innovation.”
Scott’s remarks highlight the company’s intent to streamline its offerings, reduce complexity for customers, and strengthen its position as a global leader in the increasingly competitive radiopharma landscape.
Comprehensive Portfolio of PET Imaging Agents
Under the unified brand, Siemens Healthineers will continue to develop and supply a wide range of PET radiopharmaceuticals used across multiple clinical areas. These include:
- FDG (Fluorodeoxyglucose), one of the most widely used PET tracers for oncology, neurology, and cardiology applications
- PSMA-targeted PET agents, including the CDMO-manufactured product POSLUMA®, developed by Blue Earth Diagnostics
- Diagnostic radiopharmaceuticals for Alzheimer’s disease, enabling early detection of amyloid pathology
- PET agents used in cardiac imaging, supporting assessments of perfusion and viability
- Other specialized agents tailored to experimental, investigational, and commercial imaging needs
PETNET Solutions, in particular, has long been recognized for its ability to manufacture and distribute a wide spectrum of diagnostic imaging agents across the United States. With short-lived isotopes such as Fluorine-18 requiring tight control of timing, logistics, and cold-chain distribution, PETNET’s operational expertise remains a major asset in Siemens Healthineers’ radiopharma portfolio.
AdAcAp Molecular Imaging brings complementary strengths, particularly in the European market, where its facilities have played key roles in advancing access to next-generation theranostic agents.
Supporting the Growing Field of Theranostics
One of the key drivers behind Siemens Healthineers’ brand consolidation is the explosive growth of theranostics. This approach pairs specific imaging agents with targeted therapies—often radioligand therapies—that can precisely locate and treat cancer cells.
PET imaging agents, such as PSMA-targeted tracers for prostate cancer, are essential for identifying patients who may benefit from these therapies and for monitoring treatment outcomes. As oncology shifts further toward personalized medicine, demand for consistent, reliable, and scalable radiopharmaceutical production is rapidly increasing.
By bringing all radiopharmaceutical businesses under one brand, Siemens Healthineers is positioning itself as a single-source partner for healthcare systems seeking to deploy or expand theranostic services.
Enhanced Integration for Customers and Patients
The transition to a unified Siemens Healthineers identity aims to simplify the customer experience across multiple touchpoints—from ordering and scheduling to quality assurance, logistics, and technical support. The integrated branding will also streamline communication, training, and regulatory processes across the global network.
For patients, the change translates into improved access to high-quality radiopharmaceuticals and more reliable supply continuity. With the addition of AdAcAp Molecular Imaging’s European facilities into Siemens Healthineers’ network, the company is better equipped to respond to fluctuations in demand, geographic distribution challenges, and future expansion of theranostic offerings.
A Strong Foundation for Future Growth
Over the next year, Siemens Healthineers will complete the rebranding process across all relevant facilities, digital platforms, regulatory filings, and product labeling. The organizational integration is expected to create a stronger foundation for research and development, enabling the company to accelerate the introduction of new imaging agents and theranostic solutions.
With an unrivaled global footprint, deep technical expertise, and expanding therapeutic partnerships, Siemens Healthineers is positioning itself to shape the next era of molecular imaging and precision medicine.
